CORMEDIX INC
CORMEDIX INC logo
CRMD

CORMEDIX INC (CRMD)

$3.969.59%

Market is closed
– opens on 8 PM, 07 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$3.96
Day's Range
$4.42
$2.65
52-Week Range
$8.03
1 month return34.69%
3 month return11.24%
1 year return19.68%
5 year return44.03%

Company Information

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin™ is CE Marked and marketed in Europe and other territories as a medical device.
OrganizationCORMEDIX INC
Employees29
CEODr. Matthew T. David M.D.
IndustryHealth Technology

Analyst Recommendation

based on 3 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 3 Wall street analysts offering stock ratings for CORMEDIX INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 278.79%

Current

$3.96

Target

$15.0

Recommendation Trend

Based on 3 analyst

Current1M Ago3M Ago
Buy
3
8
8
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
180.8M
Book Value
$1.37
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.73
PEG Ratio
0.0
Wall Street Target Price
15.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
3.26
Enterprise Value
125.5M
Enterprise Value/Revenue
1363.03
Enterprise Value/Ebitda
-4.22

Technicals

Beta
2.33
50 Day MA
3.29
200 Day MA
3.95

Institutional Holdings

Nomura Holdings Inc

7.15%

Vanguard Group Inc

4.35%

Elliott Investment Management L.P.

3.76%

Barclays PLC

1.82%

Millennium Management LLC

1.66%

BlackRock Inc

1.53%

Discover more

Frequently Asked Questions

What is CORMEDIX INC share price today?

Can Indians buy CORMEDIX INC shares?

How can I buy CORMEDIX INC shares from India?

Can Fractional shares of CORMEDIX INC be purchased?

What are the documents required to start investing in CORMEDIX INC stocks?

What are today’s High and Low prices of CORMEDIX INC?

What are today’s traded volumes of CORMEDIX INC?

What is today’s market capitalisation of CORMEDIX INC?

What is the 52 Week High and Low Range of CORMEDIX INC?

How much percentage CORMEDIX INC is down from its 52 Week High?

How much percentage CORMEDIX INC is up from its 52 Week low?

What are the historical returns of CORMEDIX INC?

Who is the Chief Executive Officer (CEO) of CORMEDIX INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*